Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 9/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.34 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31377182 | 0.90 | NPC1 (0.35) | HCAR3NPC1GRM2 | |
| SCHEMBL24494651 | 0.87 | HCAR3 (0.37) | HCAR3NPC1NAMPTMAPTCTNNB1 | |
| SCHEMBL29699167 | 0.87 | HCAR3 (0.37) | HCAR3NPC1NAMPTMAPTCTNNB1 | |
| SCHEMBL31666996 | 0.83 | POLB (0.41) | HCAR3NPC1NAMPTMAPT | |
| SCHEMBL2144514 | 0.82 | NPC1 (0.40) | HCAR3NPC1NAMPTMAPT | |
| SCHEMBL19023657 | 0.82 | SLC9A1 (0.39) | HCAR3NPC1GRM2 | |
| SCHEMBL30991716 | 0.82 | SLC9A1 (0.39) | HCAR3NPC1GRM2 | |
| SCHEMBL3782203 | 0.82 | DGAT1 (0.42) | HCAR3NPC1 | |
| SCHEMBL23619038 | 0.82 | HCAR3 (0.38) | HCAR3NPC1NAMPT | |
| SCHEMBL6729750 | 0.79 | HCAR3 (0.39) | HCAR3NPC1NAMPTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022116998-A1 | FUSED HETEROCYCLIC DERIVATIVES AS HBV INHIBITORS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022116998-A1 | FUSED HETEROCYCLIC DERIVATIVES AS HBV INHIBITORS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-06-09 | — | — | WO | disclosed |
| US-20040127507-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-07-01 | — | — | US | disclosed |
| US-20040122026-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-24 | — | — | US | disclosed |
| US-20030225288-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003087063-A1 | IMIDAZOLIDINE COMPOUNDS AS CHEMOKINE RECEPTOR MODULATORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127507-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | HCAR3 2181/4885NPC1 401/4885NAMPT 657/4885 |
| US-20030225288-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | HCAR3 2181/4885NPC1 401/4885NAMPT 657/4885 |
| US-20040122026-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | HCAR3 2181/4885NPC1 401/4885NAMPT 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.